Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
3,025,343
-
Share change
-
-465,368
-
Total reported value
-
$3,418,775
-
Put/Call ratio
-
42%
-
Price per share
-
$1.13
-
Number of holders
-
39
-
Value change
-
-$601,055
-
Number of buys
-
16
-
Number of sells
-
21
Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q3 2016
As of 30 Sep 2016,
GALECTIN THERAPEUTICS INC - COM NEW (GALT) was held by
39 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,025,343 shares.
The largest 10 holders included
D.A. DAVIDSON & CO., VANGUARD GROUP INC, Advisor Group, Inc., JACOBS LEVY EQUITY MANAGEMENT, INC, COURAGE CAPITAL MANAGEMENT LLC, Benchmark Capital Advisors, GEODE CAPITAL MANAGEMENT, LLC, KCG Holdings, Inc., Neuberger Berman Group LLC, and US BANCORP \DE\.
This page lists
39
institutional shareholders reporting positions in this security
for the Q3 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.